Scott Matson, MD

Research Project:
Identifying Metabolic Changes in Early-Stage Pulmonary Fibrosis

Grant Awarded:

Dalsemer Interstitial Lung Disease Award

Research Topics:

biomarkers
computational biology

Research Diseases:

interstitial lung disease
pulmonary fibrosis

Idiopathic pulmonary fibrosis is a progressive scarring lung disease that leads to significant morbidity and poor survival. There are treatments for pulmonary fibrosis, however they only slow lung function decline. Patients often are diagnosed only after they have advanced disease, when the benefit of treatment is limited. Understanding molecular changes in patients with pulmonary fibrosis before they start showing symptoms is critical to improving outcomes. Early forms of pulmonary fibrosis are identified on screening computed tomography (CT) scans of the chest. They are associated with worse survival and progression to pulmonary fibrosis with symptoms. We plan to study more than 7,000 subjects to study metabolomic changes that are associated with these CT scan patterns. Our goal is to identify important markers and pathways associated with pulmonary fibrosis risk.

Dalsemer Interstitial Lung Disease Award

Page last updated: November 22, 2024

Join the Patient & Caregiver Network

How to Help People Quit

10 Tips to Protect Yourself from Unhealthy Air

State of the Air Key Findings

Become an Advocate

Register for a LUNG FORCE Walk

Double Your Gift

Scott Matson, MD

2X Your Lifesaving Impact

Make a Donation

Become a Lung Health Insider

Select Your Location

Change Language

Lung HelpLine

1-800-LUNG-USA